- NHL Treatment
- Hodgkin's Treatment
- Clinical Trials
- Monoclonal Antibodies
- Types of NHL
Lymphoma and Pets
Drug candidate to rebuild stem cells given orphan drug status
The U.S. Food and Drug Administration has granted orphan drug status designation to Tarix Pharmaceuticals' TXA127, a drug target intended to be used in the engraftment of stem cell transplant patients with myelodysplastic syndromes.
TXA127 is designed to help patients rebuild their stem cells in the wake of a stem cell transplant without causing any additional bleeding or infection.